Reumatologia最新文献

{"title":"Influenza - a problem still existing during the COVID-19 pandemic.","authors":"Lidia B Brydak","doi":"10.5114/reum/169416","DOIUrl":"https://doi.org/10.5114/reum/169416","url":null,"abstract":"Address for correspondence: Lidia B. Brydak, National Institute of Public Health – National Research Institute, 24 Chocimska St., 00-791 Warsaw, Poland, e-mail: lbrydak@pzh.gov.pl Submitted: 29.04.2023; Accepted: 12.05.2023 Influenza has always been and will be in years to come a global and public health problem. Therefore the improvement and expansion of the Global Influenza Surveillance and Response System (GISRS) should be a priority for the healthcare community [1]. In 1947, at the 4th International Congress of Microbiologists in Copenhagen, the World Health Organization (WHO) foundations were laid for the future GISRS (which was finally created in 1952 and in 2022 celebrated its 70th anniversary) with the establishment of the first seven WHO Collaborating Centers for Reference and Research on Influenza in their current form. Since 1957 Poland has been participating in this system for monitoring influenza, as one of 149 National Influenza Centers worldwide. Poland was responsible for the introduction of the SENTINEL surveillance methods during its leadership of GISRS in the 2004/2005 epidemic season [2]. Virological data obtained by the Collaborating Centers for Reference and Research on Influenza are reported to the WHO and the European Union Agency: European Centre for Disease Prevention and Control (ECDC) [3]. As an example of such data, the information provided to the WHO by Poland concerning epidemic seasons from 2015/2016 to 2022/2023, including the time when the COVID-19 pandemic took place, is presented in Table I. On March 11, 2020, the WHO announced the COVID-19 pandemic. As shown in Table I, the values of all the indicators used for influenza monitoring were definitely lower at the time of the pandemic. This phenomenon is attributed to the fact that a significant part of the population worked remotely, including schools and universities, and mandates to wear masks were introduced to avoid the transmission of respiratory infections. The number of deaths resulting from post-influenza complications reported in Poland is underestimated – which is true not only in the case of data presented in Table I, as some deaths are attributed to the wrong disease entity. In the 2021/2022 epidemic season, i.e. from October 1, 2021 to September 30, 2022, a total of 2,317 samples","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/cc/RU-61-169416.PMC10373163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9913645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence and correlation of depression and anxiety with disease activity in rheumatoid arthritis.","authors":"Sousan Moudi,&nbsp;Behzad Heidari,&nbsp;Behnaz Yousefghahari,&nbsp;Reza Gholami,&nbsp;Hemmat Gholinia,&nbsp;Mansour Babaei","doi":"10.5114/reum/154905","DOIUrl":"https://doi.org/10.5114/reum/154905","url":null,"abstract":"<p><strong>Introduction: </strong>Depression and anxiety share similar symptoms with rheumatoid arthritis (RA) and these conditions are often not diagnosed or overlooked in RA. This study aimed to determine the prevalence of depression/anxiety in RA and their correlation with RA activity.</p><p><strong>Material and methods: </strong>Rheumatoid arthritis patients who presented at a rheumatology clinic were selected consecutively. The diagnosis of RA was confirmed by the ACR/EULAR criteria, disease activity was assessed by Disease Activity Score based on the 28-joint count (DAS28) and patients with DAS28 > 2.6 were considered to have active RA. The diagnosis of depression and anxiety was made by the Hospital Anxiety and Depression Scale (HADS). The Pearson test was used to determine the correlation between DAS28 and HADS scores.</p><p><strong>Results: </strong>Two-hundred patients (female, 82%) with a mean age of 53.5 ±10.1 years and mean disease duration of 6.6 ±6.8 years were studied. Depression was diagnosed in 27 (13.5%) patients and anxiety in 38 (19%) patients. The DAS28 score correlated positively with depression (<i>r</i> = 0.173, <i>p</i> = 0.014) and anxiety score (<i>r</i> = 0.229, <i>p</i> = 0.001). In multiple logistic regression analysis after adjustment for all covariates, age < 40 years and female sex were independently associated with RA activity in patients with depression, with OR = 4.21 (<i>p</i> = 0.002) and OR = 3.56 (<i>p</i> = 0.028) respectively.</p><p><strong>Conclusions: </strong>These findings indicate that depression and anxiety are prevalent in RA and correlate positively with active disease in particular in depressive female patients aged < 40 years.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/6d/RU-61-154905.PMC10201383.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9510011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of antiresorptive agents on body composition: a case-control retrospective study.","authors":"Suhel Gabriele Al Khayyat,&nbsp;Giuseppe Fogliame,&nbsp;Edoardo Conticini,&nbsp;Virginia Berlengiero,&nbsp;Paolo Falsetti,&nbsp;Stefano Gentileschi,&nbsp;Caterina Baldi,&nbsp;Marco Bardelli,&nbsp;Luca Cantarini,&nbsp;Bruno Frediani","doi":"10.5114/reum.2023.124335","DOIUrl":"https://doi.org/10.5114/reum.2023.124335","url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis is the most represented metabolic bone disease and is characterized by the reduction of bone mineral density (BMD), exposing patients to high fracture risk and disability. Bisphosphonates (BPs) are the main compounds exploited in treatment of osteoporosis and significantly reduce fracture risk. Sarcopenia is the pathological reduction of muscle masses and strength, and many studies highlighted its co-existence in patients with impaired bone mass. Indeed, the pathological reduction of lean tissue has been linked to a higher risk of falls and, consequently, fractures and disability. Moreover, the pathological reduction of lean tissue seems to share many pathological mechanisms with impaired bone strength and structure; thus, in this context, we decided to conduct a retrospective case-control study aimed at evaluating the effects of BPs on lean mass and body composition.</p><p><strong>Material and methods: </strong>We enrolled postmenopausal women from our metabolic bone diseases outpatient clinic who underwent at least two consecutive dual-energy X-ray absorptiometry (DXA) examinations concomitantly to the beginning of an antiresorptive agent. The body composition of patients and controls was compared by fat masses, lean masses and android-to-gynoid ratio (A/G ratio).</p><p><strong>Results: </strong>A total of 64 female subjects were considered for the study: 41 starting a BPs and 23 without treatment were used as control. The fat masses and lean masses appeared to be unaffected by BPs. Conversely, A/G ratio was lower in BPs group after 18 months of therapy compared to baseline (<i>p</i> < 0.05). From the stratification based on the single BP we failed to highlight any significant difference between the tested variables.</p><p><strong>Conclusions: </strong>Bisphosphonates treatment did not modify lean tissues, however a significant reduction of A/G ratio in BP group was documented. Thus the BPs seems to act on patients body composition and extra-skeletal tissues but larger prospective studies are needed to evaluate whether these modifications have clinical relevance.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/2c/RU-61-156907.PMC10201384.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9521982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis and diabetes - possible links and diagnostic difficulties.","authors":"Joanna Magdalena Tomasiuk,&nbsp;Anna Nowakowska-Płaza,&nbsp;Małgorzata Wisłowska,&nbsp;Piotr Głuszko","doi":"10.5114/reum/170048","DOIUrl":"https://doi.org/10.5114/reum/170048","url":null,"abstract":"<p><strong>Objectives: </strong>In this review, the authors aimed to clarify the relationship between the occurrence of osteoporosis and diabetes, analyze the differences between the pathogenesis of osteoporosis in different types of diabetes and propose the most effective diagnostic strategy and fracture risk assessment in diabetic patients.</p><p><strong>Material and methods: </strong>A analysis of publications in MEDLINE, COCHRANE and SCOPUS databases was performed, searching for reports on the diagnostics, fracture risk assessment, prevention, and treatment of osteoporosis in patients with diabetes mellitus (DM) published in the years 2016-2022. The key words for the search were: diabetes, osteoporosis, and low-energy fracture.</p><p><strong>Results: </strong>Bone complications of T1DM are more severe than T2DM, because of the lack of anabolic effect of insulin on bones. In T2DM the risk of fractures is elevated; however, identifying the mechanisms underlying the increased risk of fractures in T2DM is not clear. The FRAX tool is not appropriate for assessing the fracture risk in young patients with T1DM. It is quite useful in older patients with T2DM, but in these patients the calculated fracture risk may be underestimated. In T2DM the fracture risk often does not correspond to BMD value as measured by dual-energy X-ray absorptiometry (DXA). Diagnostic tools such as the trabecular bone score may play a significant role in this group of patients. Conclusions: Optimal strategies to identify and treat high risk individuals require further research and proper definition. The diagnostic criteria for osteoporosis should be clearly defined as well as fracture risk assessment and choice of anti-osteoporotic medication. In all cases of secondary osteoporosis, treatment of the underlying disease is the most important. The relationship between high risk of fractures and diabetes is inseparable, and its full understanding seems to be the key to effective management.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/ba/RU-61-170048.PMC10515121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41134723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following immunisation with COVID-19 vaccines: a 15 months update.","authors":"Ciro Manzo, Alberto Castagna, Arvind Nune, Marco Isetta","doi":"10.5114/reum/172508","DOIUrl":"https://doi.org/10.5114/reum/172508","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlapping clinical features of systemic juvenile idiopathic arthritis and SARS-CoV-2-related multisystem inflammatory syndrome in children.","authors":"Oksana Boyarchuk,&nbsp;Tetiana Kovalchuk","doi":"10.5114/reum/161185","DOIUrl":"https://doi.org/10.5114/reum/161185","url":null,"abstract":"<p><strong>Introduction: </strong>Differential diagnosis of the systemic juvenile idiopathic arthritis (sJIA) is often complicated, because of the variability in clinical presentation and the absence of specific signs.</p><p><strong>Material and methods: </strong>The PubMed/Medline and Scopus databases from the years 2013-2022 were analysed for full articles in English and the following key words were used: \"juvenile idiopathic arthritis\" and \"MIS-C\"; \"juvenile idiopathic arthritis\" and \"Kawasaki disease\". As an example of the problem the case description of a 3-year-old patient is presented.</p><p><strong>Results: </strong>In the first step 167 publications were identified; however, after exclusion of duplicated articles and those not relevant to the topic, only 13 were included in the analysis. We analysed studies that describe overlapping clinical features of sJIA and Kawasaki disease (KD) or multisystem inflammatory syndrome in children (MIS-C). The main issues we discussed were the search for the specific features that would distinguish one disease from another. Fever refractory to intravenous immunoglobulin treatment was the most frequent indicator among the features of clinical courses. Among other clinical signs prolonged, recurrent fever, rash, an incomplete KD phenotype, Caucasian race, splenomegaly, and complicated macrophage activation syndrome also supported sJIA diagnosis. Among laboratory tests, high ferritin and serum interleukin-18 levels were found to be the most useful in differentiation. The present case demonstrates that prolonged, unexplained, recurrent fever with a specific pattern should be the reason to suspect sJIA.</p><p><strong>Conclusions: </strong>Overlapping features of sJIA and SARS-CoV-2-related MIS-C complicates diagnosis in the era of the COVID-19 pandemic. Our case presentation adds symptoms of prolonged, spiking, unexplained, recurrent fever with a specific pattern for supporting systemic juvenile idiopathic arthritis diagnosis.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/30/RU-61-161185.PMC10044031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9225972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matrix metalloproteinases in rheumatoid arthritis and osteoarthritis: a state of the art review.","authors":"Łukasz Pulik,&nbsp;Paweł Łęgosz,&nbsp;Gabriela Motyl","doi":"10.5114/reum/168503","DOIUrl":"https://doi.org/10.5114/reum/168503","url":null,"abstract":"<p><p>Although the pathological mechanisms involved in osteoarthritis (OA) and rheumatoid arthritis (RA) are different, the onset and progression of both diseases are associated with several analogous clinical manifestations, inflammation, and immune mechanisms. In both diseases, cartilage destruction is mediated by matrix metalloproteinases (MMPs) synthesized by chondrocytes and synovium fibroblasts. This review aims to summarize recent articles regarding the role of MMPs in OA and RA, as well as the possible methods of targeting MMPs to alleviate the degradation processes taking part in OA and RA. The novel experimental MMP-targeted treatments in OA and RA are MMP inhibitors eg. 3-B2, taraxasterol, and naringin, while other treatments aim to silence miRNAs, lncRNAs, or transcription factors. Additionally, other recent MMP-related developments include gene polymorphism of MMPs, which have been linked to OA susceptibility, and the MMP-generated neoepitope of CRP, which could serve as a biomarker of OA progression.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/66/RU-61-168503.PMC10373173.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9913640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EULAR. European Congress of Rheumatology: Milan, 31 May-3 June 2023.","authors":"","doi":"10.5114/reum/169417","DOIUrl":"10.5114/reum/169417","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/35/RU-61-169417.PMC10373171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10255645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity in rheumatological practice.","authors":"Jarosław Kozakowski,&nbsp;Piotr Dudek,&nbsp;Wojciech Zgliczyński","doi":"10.5114/reum/170401","DOIUrl":"https://doi.org/10.5114/reum/170401","url":null,"abstract":"<p><p>Obesity is a chronic disease that leads to the development of secondary metabolic disturbances and diseases and strongly contributes to increased morbidity and mortality. On the other hand, musculoskeletal disorders are currently the main cause of disability and the second most frequent reason for visits to the doctor. Many studies clearly show that excessive body weight adversely affects the course of almost all musculoskeletal system diseases, from osteoarthritis, through metabolic, systemic connective tissue, to rarely diagnosed diseases. The impact of increased fat mass on the musculoskeletal system is presumably complex in nature and involves the influence of biomechanical, dietary, genetic, inflammatory and metabolic factors. Due to the epidemic nature of obesity and its serious health consequences, this disease requires energetic treatment. It is always based on lifestyle modification enriched, if necessary, by pharmacological and, in justified cases, surgical treatment.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/e3/RU-61-170401.PMC10515124.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peculiarities of clinical signs, course and treatment of musculoskeletal system lesions in post-COVID syndrome.","authors":"Larysa Voloshyna, Svitlana Smiyan, Oleksandr Voloshyn, Inna Buzdugan, Olga Bukach, Natalia Voloshynovych, Oleksandra Doholich","doi":"10.5114/reum/172575","DOIUrl":"10.5114/reum/172575","url":null,"abstract":"<p><strong>Introduction: </strong>Post-COVID syndrome (PCS) is a frequent phenomenon of patients who have suffered from an acute attack of COVID-19 infection, and it is characterized by a wide range of symptoms from different organs and systems including the musculoskeletal system (MSS). However, peculiarities of MSS lesions have not been sufficiently studied to date, in particular, in the aspect of the therapeutic process. We aimed to investigate peculiarities of MSS lesions in patients with PCS.</p><p><strong>Material and methods: </strong>Observations were carried out in 142 patients with PCS and MSS lesions. The age of patients was 36-67 years. Up-to-date methods of disease verification were used. An acute period of COVID-19 in all the patients was of moderate severity without oxygen support.</p><p><strong>Results: </strong>Musculoskeletal system lesions in patients with PCS were found to appear 1-4 weeks after the experienced acute period of COVID-19 infection. Against the background of significant arthralgia (100%) in 93 (65.5%) patients manifestations of acute arthritis were detected, the frequency of which increased with age. Musculoskeletal system lesions were found against the background of dominating PCS manifestations from the cardiovascular and digestive systems. Deterioration of the course and results of treatment of diseases caused by an age-related polymorbid background was determined. Certain difficulties in the treatment of MSS lesions by means of non-steroidal anti-inflammatory drugs and limitation in the use of glucocorticosteroids are caused by severe gastroduodenopathy and arterial hypertension. Long-term, up to 6 months, administration of L-arginine, L-carnitine and quercetin in the rehabilitation complex improved the overall results of treatment of PCS manifestations including arthropathy.</p><p><strong>Conclusions: </strong>Musculoskeletal system lesions in patients with PCS are not the main constituent of this syndrome. Difficulties in the treatment of arthropathy are due to the signs of gastroduodenopathy and arterial hypertension. Additional administration of L-arginine, L-carnitine and quercetin is reasonable.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}